Yang, S.-J.S.-J.YangTseng, S.-Y.S.-Y.TsengWang, C.-H.C.-H.WangYoung, T.-H.T.-H.YoungShieh, M.-J.M.-J.ShiehMING-JIUM SHIEHTAI-HORNG YOUNG2021-02-042021-02-042019https://www.scopus.com/inward/record.url?eid=2-s2.0-85087049744&partnerID=40&md5=ceb8cbb1dc519d28d886688b91e4327fhttps://scholars.lib.ntu.edu.tw/handle/123456789/547061Colorectal cancer is now one of the major diseases in the world. With westernized diet in Taiwan, the incidence of colorectal cancer increases. For cancer stem cell therapy, CD133 (prominin-1) is a theoretical cancer stem cell (CSC) marker for colorectal cancer and is a proposed therapeutic target. Cells with CD133 overexpression have demonstrated enhanced tumor-initiating ability and tumor relapse probability [1-6]. To resolve the problem of chemotherapy failure, we will develop a magnetite-based nanomedicine using loco-regional hyperthermia combined with chemotherapy. The targeting carrier has a magnetite nanoparticle (superparamagnetic iron oxide nanoparticles, SPIO) core and a layer-by-layer polyelectrolyte molecule shell that carries irinotecan (CPT-11) and anti-human prominin-1 (PROM1/CD133) monoclonal antibody for cancer stem cell-specific targeting. Besides as a contrast agent for MRI, this nanomedicine plays as an important role to relay the externally delivered radiofrequency energy for tumor hyperthermia [7,8]. Locoregional heat can trigger a drug release from the carrier as it directly damages tumor cells and cancer stem cells.. Finally, the use of this nanomedicine can improve the half-life of chemotherapy drugs in the blood and reduce the side effect, and is significantly more efficacious than hyperthermia or chemotherapy alone for colorectal cancer therapy. ? 2019, Avestia Publishing.[SDGs]SDG3conference paper10.11159/icnnfc19.1122-s2.0-85087049744